GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Market Cap

Alnylam Pharmaceuticals (BSP:A1LN34) Market Cap : R$190,350 Mil (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alnylam Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was R$75.21. Alnylam Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 2,577 Mil. Therefore, Alnylam Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was R$193,803 Mil.

Alnylam Pharmaceuticals's quarterly market cap increased from Mar. 2024 (R$91,635 Mil) to Jun. 2024 (R$172,956 Mil) and increased from Jun. 2024 (R$172,956 Mil) to Sep. 2024 (R$193,803 Mil).

Alnylam Pharmaceuticals's annual market cap increased from Dec. 2021 (R$113,043 Mil) to Dec. 2022 (R$156,146 Mil) but then declined from Dec. 2022 (R$156,146 Mil) to Dec. 2023 (R$112,334 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alnylam Pharmaceuticals's Enterprise Value for Today is R$181,417 Mil.


Alnylam Pharmaceuticals Market Cap Historical Data

The historical data trend for Alnylam Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Market Cap Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 74,396.85 113,043.19 156,145.50 112,334.04

Alnylam Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107,087.53 112,334.04 91,635.09 172,956.37 193,802.63

Competitive Comparison of Alnylam Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Market Cap falls into.



Alnylam Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alnylam Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=R$44.65*2515.88
=R$112,334

Alnylam Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=R$75.21*2576.82
=R$193,803

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals  (BSP:A1LN34) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Alnylam Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals Headlines

No Headlines